Back to mobile site

BTIG on Praxis Precision Medicines Inc. (PRAX): NDA acceptance offers clean regulatory setup for approval

April 14, 2026 11:46 AM EDT Send to a Friend
BTIG analyst Kambiz Yazdi reiterated a Buy rating and $843.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login